Safety and Efficacy of Sacubitril/Valsartan in Patients With a Failing Systemic Right Ventricle: A Prospective Single-Center Study
Authors' conclusion
Our data showed that sacubitril/valsartan is well tolerated and is associated with systemic right ventricle remodeling and improved systolic function as well as improved clinical status
Study context
- Population
- Patients with transposition of the great arteries after Senning/Mustard or congenitally corrected transposition with impaired systemic RV systolic function35% ccTGA
- Participants
- 50 patients
- Exposure
- Sacubitril/valsartan, baseline vs 1 year
- Outcome
- Safety and efficacy; primary efficacy end points NT-proBNP and systolic function improvement
- Follow-up
- 1 year
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- NT-proBNP decreased significantly immediately after treatment initiation, returned to baseline at 1 year
- 1-year follow-up vs Baseline: P < 0.001
- 1-year follow-up vs Baseline: P < 0.001
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Baseline | P value |
|---|---|---|
| 6-minute walk distance · 1 year1 year vs Baseline | 425 (IQR 333–480) m | P < 0.001 |
- 6-minute walk distance: 1 year 500 (IQR 443–560) m
NYHA class change · 1 year
- NYHA class change
- P < 0.001
Quality of life · 1 year
- Improved quality of life
Tricuspid regurgitation severity
- Improved only in transposition of the great arteries patients
- P = 0.006
Target dose
- Target dose reached
- 20 (42%)
- Beneficial effects irrespective of anatomy, more pronounced on target dose
Safety
Adverse events · 1 year
- Major adverse events
- 0
- Ceased treatment due to hypotension
- 2 (4%)
- Nephrotic syndrome
- 1 (2%)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Safety and Efficacy of Sacubitril/Valsartan in Patients With a Failing Systemic Right Ventricle: A Prospective Single-Center Study. Circ Heart Fail. Published 2 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →